Gland Pharma reports 41 percent jump in Q1 revenue
Gland Pharma, majority owned by China's Shanghai Fosun Pharmaceutical Group Co, however, reported a 15.3% fall in profit to 1.94 billion rupees for the quarter ended June 30 amid price erosions and increased competition.
Hyderabad: Indian generic injectables maker Gland Pharma Ltd reported a 41% jump in first-quarter revenue on Monday, aided by its acquisition of French pharmaceutical group Cenexi.
The Hyderabad-based company, which draws the bulk of its revenue from the United States, Europe, Canada, Australia and New Zealand, said revenue jumped to 12.09 billion Indian rupees ($146.13 million) from 8.57 billion rupees.
The company said 37% of the total revenue came from its acquisition of Cenexi in January. Revenue from Europe jumped more than five-fold to 2.22 billion rupees.
Excluding the Cenexi acquisition, Gland Pharma's revenue rose 3.5% on the back of improvement in its base business and stability in the United States.
"The efforts made for business recovery, after a challenging previous year, are yielding fruitful results," Gland Pharma Chief Executive Officer Srinivas Sadu said in a statement.
Gland Pharma, majority owned by China's Shanghai Fosun Pharmaceutical Group Co, however, reported a 15.3% fall in profit to 1.94 billion rupees for the quarter ended June 30 amid price erosions and increased competition.
Gland Pharma, founded in 1978, primarily operates on a business-to-business model and focuses on sterile and complex injectables. The company also has contract manufacturing, along with direct consumer sales.
Sales in the Indian market, which accounts for 5% of its total revenue, rose 29% to 647 million rupees.
Gland Pharma also said it launched cardioprotective agent Dexrazoxane in China during the quarter, the company's first product in the country.
Read also: Gland Pharma reports 56 percent decline in Q4 profit on soft demand
